74502850
reacted to and commented on
$Esperion Therapeutics (ESPR.US)$Undervalued Stock with a Game-Changing Statin Alternative
This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to m...
This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to m...

33
8
1
74502850
reacted to and commented on
$Esperion Therapeutics (ESPR.US)$Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination ...
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination ...



6
4
74502850 : Well written and some good facts. We continue to prescribe Nexlizet 1st before PCSK9 injections and that will help the company catch up to Repatha sales. The beauty is Nexlizet is a once a day pill and provides an extra layer of protection by lowering hscrp, sadly PCSK9 injections don't. (972)-649-6511. Heartplace Texas.